Form 4: Co-Diagnostics, Inc. (CODX), Serbin Richard S, transaction 11/23/2022

Summary

A Form 4 filed with the Securities and Exchange Commission by Richard Serbin, a director of Co-Diagnostics, Inc. (CODX), with a single vesting event on 11/23/2022: 11,667 restricted stock units converted into the same number of common shares, bringing the direct ownership to 26,667 shares. Table II shows 70,833 units still owned. According to the footnote, the units belong to a grant of 37,500 units made January 8, 2021 and a grant of 70,000 units made July 11, 2022, both pursuant to the Co-Diagnostics, Inc. 2015 Long Term Incentive Plan. The form is signed /s/ Richard Serbin and dated 11/23/2022.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

SEC Form 4

FORM 4 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 | OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB APPROVAL | OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB Number: | 3235-0287 | Estimated average burden | hours per response: | 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person * SERBIN RICHARD S (Last) (First) (Middle) 2401 S. FOOTHILL DRIVE SUITE D (Street) SALT LAKE CITY UT 84109 (City) (State) (Zip) | SERBIN RICHARD S | (Last) | (First) | (Middle) | 2401 S. FOOTHILL DRIVE SUITE D | SALT LAKE CITY | UT | 84109 | (City) | (State) | (Zip) | 2. Issuer Name and Ticker or Trading Symbol Co-Diagnostics, Inc. [ CODX ] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title below) Other (specify below) | X | Director | 10% Owner | Officer (give title below) | Other (specify below)
3. Date of Earliest Transaction
 (Month/Day/Year) 11/23/2022
4. If Amendment, Date of Original Filed
 (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person | X | Form filed by One Reporting Person | Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr.
 3) | 2. Transaction Date
 (Month/Day/Year) | 2A. Deemed Execution Date, if any
 (Month/Day/Year) | 3. Transaction Code (Instr.
 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr.
 3, 4 and 5) | 5.
 Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 7. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | Amount | (A) or (D) | Price
Common Stock | 11/23/2022 | A | 11,667 (1) | A | $ 0.00 | 26,667 | D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr.
 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date
 (Month/Day/Year) | 3A. Deemed Execution Date, if any
 (Month/Day/Year) | 4. Transaction Code (Instr.
 8) | 5.
 Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr.
 3, 4 and 5) | 6. Date Exercisable and Expiration Date
 (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr.
 3 and 4) | 8. Price of Derivative Security (Instr.
 5) | 9.
 Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 11. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares
Restricted Stock Units | $ 0.00 | 11/23/2022 | M | 11,667 | (1) | (1) | Common Stock | 82,500 | $ 0.00 | 70,833 | D
Explanation of Responses:
1. Included in 37,500 restricted stock units awarded to the Reporting Person on January 8, 2021, pursuant to the Co-Diagnostics, Inc. 2015 Long Term Incentive Plan, and vest in three equal installments every twelve months commencing on January 8, 2021.

Included in 70,000 restricted stock units awarded to the Reporting Person on July 11, 2022, pursuant to the Co-Diagnostics, Inc. 2015 Long Term Incentive Plan, and vest in 6 equal installments every 6 months commencing on November 23, 2022.
Remarks:
/s/ Richard Serbin | 11/23/2022
** Signature of Reporting Person | Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction
 4

 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

File and source

File

SEC_CODX_4_filed2022-11-23_0001562180-22-007857.xml

Size

16,563 bytes

SHA-256

a14f65396c6c107879ac3e2cb887fe4b1bd2ae366d3e8a61ae25b7b45a2df451

Our copy

SEC_CODX_4_filed2022-11-23_0001562180-22-007857.xml

Original

www.sec.gov